ABSTRACT
During atherogenesis, circulating macrophages migrate into the subendothelial space, internalize cholesterol-rich lipoproteins, and become foam cells by progressively accumulating cholesterol esters. The inhibition of macrophage acyl coenzyme A:cholesterol acyltransferase (ACAT), which catalyzes the formation of cholesterol esters, has been proposed as a strategy to reduce foam cell formation and to treat atherosclerosis. We show here, however, that hypercholesterolemic LDL receptor-deficient (LDLR(-/-)) mice reconstituted with ACAT1-deficient macrophages unexpectedly develop larger atherosclerotic lesions than control LDLR(-/-) mice. The ACAT1-deficient lesions have reduced macrophage immunostaining and more free cholesterol than control lesions. Our findings suggest that selective inhibition of ACAT1 in lesion macrophages in the setting of hyperlipidemia can lead to the accumulation of free cholesterol in the artery wall, and that this promotes, rather than inhibits, lesion development.
Subject(s)
Arteriosclerosis/genetics , Macrophages/enzymology , Receptors, LDL/deficiency , Sterol O-Acyltransferase/deficiency , Animals , Aorta/metabolism , Aorta/pathology , Arteriosclerosis/metabolism , Arteriosclerosis/pathology , Bone Marrow Transplantation , Cell Transplantation , Cholesterol/metabolism , Coloring Agents , Female , Immunohistochemistry , Liver/cytology , Liver/embryology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Sterol O-Acyltransferase/antagonists & inhibitors , Up-RegulationABSTRACT
Cholesterol, the chief sterol found in vertebrates, exists both as a free sterol and as a component of cholesterol esters, which are synthesized by acyl-CoA:cholesterol acyltransferase (ACAT) enzymes. Considerable knowledge concerning cholesterol ester metabolism has accumulated during the past century. However, rapid advances have occurred in the past 7 years since the cloning of an ACAT gene, including the discovery that two ACATs function in mammalian biology. A clearer picture of the functions of ACAT enzymes in cellular cholesterol metabolism and physiologic processes is now emerging. These insights may have relevance for the development of ACAT inhibitors for treating hypercholesterolemia or atherosclerosis in humans.
Subject(s)
Cholesterol Esters/biosynthesis , Sterol O-Acyltransferase/metabolism , Amino Acid Sequence , Arteriosclerosis/prevention & control , Cells, Cultured , Cholesterol Esters/history , Cloning, Molecular , DNA, Complementary/analysis , Disease Models, Animal , Drug Design , Endoplasmic Reticulum/enzymology , Enzyme Inhibitors/classification , Gene Expression Regulation, Enzymologic , History, 19th Century , History, 20th Century , Isoenzymes/genetics , Microsomes/enzymology , Molecular Sequence Data , Molecular Structure , RNA, Messenger/analysis , Sterol O-Acyltransferase/genetics , Sterol O-Acyltransferase/historyABSTRACT
The importance of cholesterol ester synthesis by acyl CoA:cholesterol acyltransferase (ACAT) enzymes in intestinal and hepatic cholesterol metabolism has been unclear. We now demonstrate that ACAT2 is the major ACAT in mouse small intestine and liver, and suggest that ACAT2 deficiency has profound effects on cholesterol metabolism in mice fed a cholesterol-rich diet, including complete resistance to diet-induced hypercholesterolemia and cholesterol gallstone formation. The underlying mechanism involves the lack of cholesterol ester synthesis in the intestine and a resultant reduced capacity to absorb cholesterol. Our results indicate that ACAT2 has an important role in the response to dietary cholesterol, and suggest that ACAT2 inhibition may be a useful strategy for treating hypercholesterolemia or cholesterol gallstones.
Subject(s)
Cholelithiasis/etiology , Cholesterol, Dietary/adverse effects , Hypercholesterolemia/etiology , Sterol O-Acyltransferase/metabolism , Animals , Gallbladder/pathology , Immunity, Innate , Intestinal Absorption , Lipoproteins/blood , Lipoproteins/ultrastructure , Liver/pathology , Male , Mice , Mice, Mutant Strains , Sterol O-Acyltransferase/geneticsABSTRACT
Inhibitors of acyl CoA:cholesterol acyltransferase (ACAT) have attracted considerable interest as a potential treatment for atherosclerosis. Currently available inhibitors probably act nonselectively against the two known ACATs. One of these enzymes, ACAT1, is highly expressed in macrophages in atherosclerotic lesions, where it contributes to foam-cell formation. In this study, we examined the effects of selective ACAT1 deficiency in two mouse models of atherosclerosis. In the setting of severe hypercholesterolemia caused by deficiency in apoE or the LDL receptor (LDLR), total ACAT1 deficiency led to marked alterations in cholesterol homeostasis and extensive deposition of unesterified cholesterol in the skin and brain. Bone marrow transplantation experiments demonstrated that ACAT1 deficiency in macrophages was sufficient to cause dermal xanthomas in hyperlipidemic LDLR-deficient mice. ACAT1 deficiency did not prevent the development of atherosclerotic lesions in either apoE-deficient or LDLR-deficient mice, despite causing relatively lower serum cholesterol levels. However, the lesions in ACAT1-deficient mice were atypical in composition, with reduced amounts of neutral lipids and a paucity of macrophages in advanced lesions. Although the latter findings may be associated with increased lesion stability, the marked alterations in cholesterol homeostasis indicate that selectively inhibiting ACAT1 in the setting of severe hyperlipidemia may have detrimental consequences.
Subject(s)
Arteriosclerosis/etiology , Cholesterol/metabolism , Foam Cells/pathology , Hypercholesterolemia/genetics , Isoenzymes/physiology , Macrophages/enzymology , Sterol O-Acyltransferase/physiology , Xanthomatosis/etiology , Animals , Aorta/pathology , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Apolipoproteins E/physiology , Arteriosclerosis/enzymology , Arteriosclerosis/genetics , Arteriosclerosis/pathology , Bone Marrow Transplantation , Crosses, Genetic , Diet, Atherogenic , Foam Cells/enzymology , Hypercholesterolemia/complications , Hypercholesterolemia/enzymology , Hypercholesterolemia/pathology , Isoenzymes/deficiency , Isoenzymes/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, LDL/deficiency , Receptors, LDL/genetics , Receptors, LDL/physiology , Skin/enzymology , Skin/pathology , Sterol O-Acyltransferase/deficiency , Sterol O-Acyltransferase/genetics , Xanthomatosis/enzymology , Xanthomatosis/genetics , Xanthomatosis/pathologySubject(s)
CCAAT-Enhancer-Binding Proteins , Cholesterol/metabolism , Homeostasis , Sterols/metabolism , Transcription Factors , Animals , DNA-Binding Proteins/physiology , Humans , Liver X Receptors , Nuclear Proteins/physiology , Orphan Nuclear Receptors , Receptors, Cytoplasmic and Nuclear/metabolism , Sterol Regulatory Element Binding Protein 1ABSTRACT
OBJECTIVES: The purpose of this study was to test the hypothesis that liposomal prostaglandin E1 (TLC C-53) would result in more rapid thrombolysis, less reocclusion and smaller infarct size when administered with heparin and streptokinase in a canine thrombolysis model. BACKGROUND: In experimental animals, prostaglandin E1 has been shown to augment thrombolysis, improve coronary flow and reduce infarct size when infused directly into the left atrium. TLC C-53 is a stable preparation of prostaglandin E1 bound by phospholipid microspheres that produces fewer adverse hemodynamic effects during intravenous use. METHODS: To investigate the effects of TLC C-53 on coronary patency and infarct salvage, we studied 30 conditioned open chest dogs. After coil-induced left anterior descending coronary artery occlusion and 1 h of clot maturation, the dogs were randomly assigned to receive a 10-min intravenous infusion of either TLC C-53 (2 micrograms/kg body weight) or placebo. Both groups then received intravenous heparin and streptokinase. Hemodynamic variables and Doppler coronary flow were monitored, and myocardial blood flow was determined using radioactive microspheres. Infarct size was assessed with triphenyltetrazolium chloride staining. RESULTS: Thrombolysis time was accelerated from 79 +/- 38 to 47 +/- 9 min (mean +/- SD), and coronary patency was greater (100% vs. 50%) with TLC C-53 than with placebo (p < 0.05). Moreover, for arteries that recanalized, coronary Doppler flow and myocardial perfusion were more severely impaired with placebo. Infarct size as a percent of the area at risk was higher (p < 0.05) with placebo (51 +/- 15%) than with TLC C-53 (33 +/- 14%). Neutrophil infiltration into ischemic myocardium determined by myeloperoxidase assay was also significantly greater in the placebo group. CONCLUSIONS: TLC C-53 administered intravenously before thrombolytic therapy resulted in a significant acceleration of thrombolysis time, improvement in coronary patency and blood flow during reperfusion and a reduction in infarct size.